Cell therapy in patients with COVID-19

Phase 2

Recruiting

• Conditions: COVID-19.; COVID-19; U07.1

• Registration Number: IRCT20190717044241N3
• Lead Sponsor: Barakat Pharmaceutical Group

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Results First Posted: 1900-01-01
• Last Update Posted: 22 February 2021

Recruitment & Eligibility

• Status: Recruiting
• Sex: All
• Target Recruitment: 20

Inclusion Criteria

Persistent hypoxemia despite receiving less than 93% Saturation oxygen
Respiratory failure requires a Ventilator
Chest has multilobar infiltrates

Exclusion Criteria

Patient dissatisfaction
Pregnant patient
Age under 18 years and over 65 years
Patient with known active malignancy
Shock
Organ failure

Study & Design

• Study Type: interventional
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
Clinical response. Timepoint: 28 days-From the time of cell injection until the 28th day. Method of measurement: clinical observation by Infectious Diseases Specialist.;O2 saturation. Timepoint: Since the injection of the cell; 0,3,6 days. Method of measurement: ventilator.

Secondary Outcome Measures

Name	Time	Method
Inflammation cytokines. Il-6 & Il-10. Timepoint: On days 0,3,6,14 - from the time of cell injection. Method of measurement: Assay by the Elisa.;CD4 and CD8 markers. Timepoint: On days 0,3,6,14 - from the time of cell injection. Method of measurement: Flow Cytometry.;Evaluation of lung function. Timepoint: On days 0,14 - from the time of cell injection. Method of measurement: CT scan of the lungs.